Clinical Trial Update: Decitabine + BUCY vs BUCY Conditioning Regimen for TP53+ Myeloid Tumors Undergoing Allo-HSCT [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial evaluating decitabine in combination with a BUCY conditioning regimen versus BUCY alone for TP53+ myeloid tumors undergoing allogeneic hematopoi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allogeneic Hematopoietic Stem Cell Transplantation
• Myeloid Malignancies
• Tp53-positive Myeloid Tumors

Drugs mentioned

• BUCY conditioning regimen
• Decitabine (Decitabine)

Snippet

Sponsor: Nanfang Hospital, Southern Medical University | Conditions: TP53, Myeloid Tumors | Phase 2, Phase 3 | Status: UNKNOWN